Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context
Summary: Background: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. Methods: Summ...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396423000592 |
| _version_ | 1828001743110144000 |
|---|---|
| author | Jie Chen Fengzhe Xu Xixian Ruan Jing Sun Yao Zhang Han Zhang Jianhui Zhao Jie Zheng Susanna C. Larsson Xiaoyan Wang Xue Li Shuai Yuan |
| author_facet | Jie Chen Fengzhe Xu Xixian Ruan Jing Sun Yao Zhang Han Zhang Jianhui Zhao Jie Zheng Susanna C. Larsson Xiaoyan Wang Xue Li Shuai Yuan |
| author_sort | Jie Chen |
| collection | DOAJ |
| description | Summary: Background: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. Methods: Summary-level data of 4907 circulating protein levels were extracted from a large-scale protein quantitative trait loci study including 35,559 individuals. Genetic associations with IBD and its subtypes were obtained from the Inflammatory Bowel Disease Genetics Consortium (25,024 cases and 34,915 controls), the FinnGen study (7206 cases and 253,199 controls), and the UK Biobank study (7045 cases and 449,282 controls). MR analysis was conducted to estimate the associations between protein and IBD risk. The colocalization analysis was used to examine whether the identified proteins and IBD shared casual variants. Findings: Genetically predicted levels of 3, and 5 circulating proteins were associated with IBD and ulcerative colitis (UC), respectively. With high supporting evidence of colocalization, genetically predicted MST1 (macrophage stimulating 1) and HGFAC (hepatocyte growth factor activator) levels were inversely associated with IBD risks. The associations of STAT3 (signal transducer and activator of transcription 3), MST1, CXCL5 (C-X-C motif chemokine ligand 5), and ITPKA (inositol-trisphosphate 3-kinase A) with the risk of UC were supported by colocalization analysis. Interpretation: The proteome-wide MR investigation identified many proteins associated with the risk of IBD. MST1, HGFAC, STAT3, ITPKA, and CXCL5 deserve further investigation as potential therapeutic targets for IBD. Funding: SCL is supported by research grants from the Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123) and the Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977). XYW is supported by research grants from the National Natural Science Foundation of China (81970494) and Key Project of Research and Development Plan of Hunan Province (2019SK2041). XL is supported by research grants from the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001). |
| first_indexed | 2024-04-10T06:33:39Z |
| format | Article |
| id | doaj.art-0e4b5cde8fd24cfeb105e60aa11a923c |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-04-10T06:33:39Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-0e4b5cde8fd24cfeb105e60aa11a923c2023-03-01T04:32:05ZengElsevierEBioMedicine2352-39642023-03-0189104494Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in contextJie Chen0Fengzhe Xu1Xixian Ruan2Jing Sun3Yao Zhang4Han Zhang5Jianhui Zhao6Jie Zheng7Susanna C. Larsson8Xiaoyan Wang9Xue Li10Shuai Yuan11Department of Big Data in Health Science, School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Big Data in Health Science, School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Big Data in Health Science, School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Big Data in Health Science, School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, SwedenDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China; Corresponding author.Department of Big Data in Health Science, School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Corresponding author. School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Corresponding author. Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.Summary: Background: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. Methods: Summary-level data of 4907 circulating protein levels were extracted from a large-scale protein quantitative trait loci study including 35,559 individuals. Genetic associations with IBD and its subtypes were obtained from the Inflammatory Bowel Disease Genetics Consortium (25,024 cases and 34,915 controls), the FinnGen study (7206 cases and 253,199 controls), and the UK Biobank study (7045 cases and 449,282 controls). MR analysis was conducted to estimate the associations between protein and IBD risk. The colocalization analysis was used to examine whether the identified proteins and IBD shared casual variants. Findings: Genetically predicted levels of 3, and 5 circulating proteins were associated with IBD and ulcerative colitis (UC), respectively. With high supporting evidence of colocalization, genetically predicted MST1 (macrophage stimulating 1) and HGFAC (hepatocyte growth factor activator) levels were inversely associated with IBD risks. The associations of STAT3 (signal transducer and activator of transcription 3), MST1, CXCL5 (C-X-C motif chemokine ligand 5), and ITPKA (inositol-trisphosphate 3-kinase A) with the risk of UC were supported by colocalization analysis. Interpretation: The proteome-wide MR investigation identified many proteins associated with the risk of IBD. MST1, HGFAC, STAT3, ITPKA, and CXCL5 deserve further investigation as potential therapeutic targets for IBD. Funding: SCL is supported by research grants from the Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123) and the Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977). XYW is supported by research grants from the National Natural Science Foundation of China (81970494) and Key Project of Research and Development Plan of Hunan Province (2019SK2041). XL is supported by research grants from the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001).http://www.sciencedirect.com/science/article/pii/S2352396423000592Inflammatory bowel diseaseMendelian randomizationProteinTherapeutic target |
| spellingShingle | Jie Chen Fengzhe Xu Xixian Ruan Jing Sun Yao Zhang Han Zhang Jianhui Zhao Jie Zheng Susanna C. Larsson Xiaoyan Wang Xue Li Shuai Yuan Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context EBioMedicine Inflammatory bowel disease Mendelian randomization Protein Therapeutic target |
| title | Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context |
| title_full | Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context |
| title_fullStr | Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context |
| title_full_unstemmed | Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context |
| title_short | Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analysesResearch in context |
| title_sort | therapeutic targets for inflammatory bowel disease proteome wide mendelian randomization and colocalization analysesresearch in context |
| topic | Inflammatory bowel disease Mendelian randomization Protein Therapeutic target |
| url | http://www.sciencedirect.com/science/article/pii/S2352396423000592 |
| work_keys_str_mv | AT jiechen therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT fengzhexu therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT xixianruan therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT jingsun therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT yaozhang therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT hanzhang therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT jianhuizhao therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT jiezheng therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT susannaclarsson therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT xiaoyanwang therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT xueli therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext AT shuaiyuan therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalysesresearchincontext |